血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗急性缺血性卒中的研究进展

Advance of Glycoprotein Ⅱb/Ⅲa Antagonist in Acute Ischemic Stroke

血小板活化在血栓形成中起着重要作用,虽然阿替普酶(alteplase,rt PA)静脉溶栓是治疗急性缺血性卒中(acute ischemic stroke,AIS)的标准治疗,但国内外一直在探索联合或单独使用各类抗血小板药物在治疗AIS中的作用。抑制血小板聚集过程最后共同通路的新型抗血小板药物血小板糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂,在急性冠脉综合征(acute coronary syndrome,ACS)等心血管疾病中的安全性和有效性已得到验证,但在AIS中的作用尚存争议,本文拟就相关临床研究作一综述。

Platelet activation plays an important role in thrombosis. Although intravenous alteplase（rtPA） is the standard therapy for acute ischemic stroke（AIS）, the role of antiplatelet alone or combined with thromblysis has always been explored. Glycoprotein（GP） IIb/IIIa antagonist inhibits platelet aggregation effectively through the final common pathway. Efficacy and safety of GP Ⅱb/Ⅲa antagonist have been confirmed in acute coronary syndrome（ACS）, while results have been less consistent in AIS. Hence this paper is to make a review of clinical researches on GP Ⅱb/Ⅲa antagonist in AIS.